

Beslut vid Fru Berta Kamprads styrelsemöte 23 april 2026

FBKS-2026-25, Gabriel Adrian

Super-resolution imaging of radiation-induced DNA damage to optimize FLASH and fractionated radiotherapy across oxygenation levels and cell-cycle phases

Anslag beviljat 2027-2028

FBKS-2026-31, Mohamed Altai

Engineering Next-Generation LRRC15-Targeted Radiotheranostics for Precision Cancer Therapy and Imaging.

Anslag beviljat 2027-2028

FBKS-2026-4, Bo Baldetorp

Sidoprojektansökan till projektanslag FBKS 2022-1 Rasmus Green: Endometrial cancer specific survival model development using pooled population-based consecutive cohorts and external validation - Multicentric study based on individual patient clinical and laboratory data.

Anslag beviljat 2027

FBKS-2026-14, Mattias Belting

Strategic Maintenance and Upgrading of Advanced Cancer Research Infrastructure Platforms at the Kamprad Research Environment

Anslag beviljat 2027-2030

FBKS-2026-39, Johan Bengzon

HyperTarg iPSC-derived NK cells for Refractory Malignancies

Anslag beviljat 2027-2028

FBKS-2026-44, Anders Bjartell

Evaluation of High-Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer

Anslag beviljat 2027-2028

FBKS-2026-17, Lazaro Hiram Betancourt Nunez

Clinically Actionable Precision Biomarkers to Guide Therapy in Melanoma

Anslag beviljat 2027-2028

FBKS-2026-8, David Borg

Definitive immuno-oncology in resectable dMMRMSI-H gastric and esophageal adenocarcinoma (DIORAMA phase II study)

Anslag beviljat 2027-2028

FBKS-2026-28, Åke Borg

SCAN-B: to further expand and develop molecular biomarkers for the benefit of future breast cancer patients

Anslag beviljat 2027-2028

FBKS-2026-52, Crister Ceberg

Laboratory for Translational Radiotherapy - further developments
Anslag beviljat 2027-2028

FBKS-2026-33, Anna Darabi

An Integrated Pediatric Brain Tumor Biobank Resource Enabling Translational Research and Immuno-Oncology
Anslag beviljat 2027

FBKS-2026-29, Kristina Drott

Towards clinically actionable biomarkers for patient stratification in Mycosis Fungoides and Sézary Syndrome
Anslag beviljat 2027-2028

FBKS-2026-49, Johannes Ehinger

Modulating Mitochondrial Metabolism to Radiosensitize Head and Neck Squamous Cell Carcinoma
Anslag beviljat 2027

FBKS-2026-12, Sara Ek

Towards Precision Use of Polatuzumab-Vedotin in DLBCL: Identifying Genetic and Immune Biomarkers of Treatment Response through the POLAR-BEAR Trial
Anslag beviljat 2027-2028

FBKS-2026-13, Maria Gebre-Medhin

ARTSCAN V - Photon therapy versus proton therapy in early tonsil cancer
Anslag beviljat 2027

FBKS-2026-57, Samuel Gebre-Medhin

Variation of microsatellite size in families with Lynch syndrome - impact on cancer risk
Anslag beviljat 2027

FBKS-2026-56, Aleksander Giwercman

Loss of Y chromosome as early marker of cancer in males
Anslag beviljat 2027-2028

FBKS-2026-38, Ingrid Hedenfalk

Origins, Evolution and Early Detection of Ovarian Cancer - Spatio-Temporal and Multi-Modal Omics Analyses
Anslag beviljat 2027-2028

FBKS-2026-7, Mattias Höglund

MOLECULAR PROFILING OF BLADDER CANCER: from exploratory investigations to clinical implementation
Anslag beviljat 2027-2028

FBKS-2026-51, Karolin Isaksson

Ultraviolet Exposure Patterns and Risk of Melanoma in a Large Prospective Cohort: Associations with Tumor Histopathology and the Immune Microenvironment.
Anslag beviljat 2027

FBKS-2026-59, Tomas Jansson

Harnessing magnetic forces for glioblastoma therapies
Anslag beviljat 2027-2028

FBKS-2026-22, Keivan Javanshiri

Cognitive impairment in cancer - A SweCanCog project
Anslag beviljat 2027

FBKS-2026-1, Mats Jerkeman

Biobanking at the Department of Oncology - Securing an Infrastructure for the Decades to Come
Anslag beviljat 2027-2030

FBKS-2026-37, Helena Jernström

Interplay between host and tumor factors in breast cancer
Anslag beviljat 2027-2028

FBKS-2026-23, Karin Jirström

Toward improved subtyping and tailored treatment of pancreatic and biliary tract cancer: The CHAMP and BILLIONSTARS studies
Anslag beviljat 2027-2028

FBKS-2026-26, Marcus Järås

In vivo generation of CAR-macrophages as an off-the-shelf therapy for leukemia and lymphoma
Anslag beviljat 2027-2028

FBKS-2026-24, Göran Jönsson Hallqvist

Exploiting knowledge on the anti-melanoma immune response to develop new therapies
Anslag beviljat 2027-2028

FBKS-2026-35, Jenny Klintman

Equity in palliative care among cancer patients in Skåne - a reality? A research program to investigate equity in access to and outcome of palliative care among cancer patients in Skåne
Anslag beviljat 2027-2028

FBKS-2026-42, Niklas Landberg

Clonal hematopoiesis across human tissues in cancer patients
Anslag beviljat 2027-2028

FBKS-2026-36, Anna-Maria Larsson

Improving clinical prognostication and therapy monitoring in metastatic breast cancer through omics driven immune profiling

Anslag beviljat 2027-2028

FBKS-2026-30, Fredrik Levander

Proteomics-guided development of precision combination therapies for ovarian cancer

Anslag beviljat 2027-2028

FBKS-2026-53, Johan Linderoth

Hodgkin lymphoma: genetic and clinical features with emphasis on late effects after radiotherapy, the tumor marker TARC and experimental treatment with low dose radiotherapy in combination with immunotherapy

Anslag beviljat 2027

FBKS-2026-16, Malin Malmsjö

Equipment to enable advancing melanoma diagnostic surgery using non-invasive precision diagnostics

Anslag beviljat 2027

FBKS-2026-5, György Marko-Varga

AI-Driven Model Development with NVIDIA-Accelerated Computing for Lung Cancer and Melanoma Tumor Profiling

Anslag beviljat 2027-2028

FBKS-2026-60, Selamawit Mekuria

Project ASCEND: Achieving Screening and Cervical Cancer Elimination through iNtegration and Delivery

Anslag beviljat 2027

FBKS-2026-20, Sofie Mohlin

Cytoplasmic transcription factors in cancer: an overlooked axis driving tumor biology and therapeutic vulnerability

Anslag beviljat 2027-2028

FBKS-2026-48, Malwina Molendowska

3D bioprinted cancer models for MRI-based heterogeneity and hypoxia mapping

Anslag beviljat 2027

FBKS-2026-40, Henrik Mosén

Optimizing Preoperative Evaluation in Lung Cancer: A Retrospective Cohort Study (2008-2023)

Anslag beviljat 2027

FBKS-2026-3, Martin Nilsson

Pseudorandomized comparisons in a large national cohort of anal cancer patients

Anslag beviljat 2027-2028

FBKS-2026-21, Emma Nimeus

Development of treatment for locally recurring breast cancer and bloodbased markers for local and distant recurrences

Anslag beviljat 2027-2028

FBKS-2026-15, Lars E. Olsson

Biological guided radiotherapy enabled by serial diffusion MRI and hypoxia mapping

Anslag beviljat 2027-2028

FBKS-2026-34, Helena Persson

From genetic variants to biological function: Interpreting splicing and synonymous variants in breast cancer

Anslag beviljat 2027-2028

FBKS-2026-61, Maria Planck

Molecular characterization of lung cancer in a translational approach for improved diagnostics, treatment, and follow up

Anslag beviljat 2027-2028

FBKS-2026-62, Ann Rosendahl

Genetic, Molecular, and Lifestyle Determinants of Overweight and Obesity in Primary Breast Cancer: Implications for Clinical Outcomes

Anslag beviljat 2027-2028

FBKS-2026-45, Daniel Roth

Preclinical dose-response in PSMA radionuclide therapy with a portable CZT-based gamma camera and advanced imaging methods

Anslag beviljat 2027

FBKS-2026-50, Kabilan Sakthivel

3D breast cancer organoid models to dissect how viscoelastic tumor microenvironment regulate cancer invasion

Anslag beviljat 2027

FBKS-2026-2, Mikael Segerlantz

ALLAN 2.0: Expanding Evidence-Based Early Palliative Cancer Care by E-Health Delivery

Anslag beviljat 2027-2028

FBKS-2026-11, Johanna Sjövall

Analysis of HPV DNA in plasma in patients with HPV-positive oropharyngeal squamous cell carcinoma – a prospective study of HPV DNA levels for treatment response and surveillance

Anslag beviljat 2027-2028

FBKS-2026-27, Agatheeswaran Subramaniam

Enhancing the efficacy of cancer immunotherapies through targeted protein degradation

Anslag beviljat 2027-2028

FBKS-2026-46, Tomas Vedin

Towards Precision Perioperative Medicine: Multimodal Prediction of Surgical Complications Using Proteomics and Physiological Monitoring
Anslag beviljat 2027-2028

FBKS-2026-32, Srinivas Veerla

Decoding Genomic Instability in High-Grade Serous Ovarian Cancer Using Tumor and Liquid-Based Sequencing Integrated with Machine Learning
Anslag beviljat 2027

FBKS-2026-63, Oskar Vilhelmsson Timmermand

Eradication of therapy resistant cancer by targeting cancer initiating cells
Anslag beviljat 2027

FBKS-2026-58, Anders Wittrup

Mutation triggered cytotoxic CRISPR based therapeutic for glioblastoma
Anslag beviljat 2027-2028

FBKS-2026-9, Igor Zindovic

Advancing treatment strategies and outcomes in colorectal cancer patients with lung metastases: Real-world evidence from local and national registers
Anslag beviljat 2027-2028

FBKS-2026-47, Anders Örbom

Answering questions for translation of fractionation and combination therapy to benefit prostate cancer patients treated with PSMA-targeted radionuclide therapy
Anslag beviljat 2027